| BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors E Dudnik, N Peled, H Nechushtan, M Wollner, A Onn, A Agbarya, ... Journal of Thoracic Oncology 13 (8), 1128-1137, 2018 | 201 | 2018 |
| Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors B Waissengrin, A Agbarya, E Safadi, H Padova, I Wolf The Lancet Oncology 22 (5), 581-583, 2021 | 192 | 2021 |
| Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study G Bar-Sela, M Wollner, L Hammer, A Agbarya, E Dudnik, N Haim European Journal of Cancer 49 (5), 1058-1064, 2013 | 82 | 2013 |
| First line immunotherapy for non-small cell lung cancer NJ Nasser, M Gorenberg, A Agbarya Pharmaceuticals 13 (11), 373, 2020 | 68 | 2020 |
| Natural products as potential cancer therapy enhancers: A preclinical update A Agbarya, N Ruimi, R Epelbaum, E Ben-Arye, J Mahajna SAGE open medicine 2, 2050312114546924, 2014 | 65 | 2014 |
| Potential mechanisms of cancer-related hypercoagulability NJ Nasser, J Fox, A Agbarya Cancers 12 (3), 566, 2020 | 62 | 2020 |
| Efficacy of the mRNA-based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs A Agbarya, I Sarel, T Ziv-Baran, S Agranat, O Schwartz, A Shai, ... Cancers 13 (16), 4191, 2021 | 41 | 2021 |
| Stepping from traditional to integrative medicine: perspectives of Israeli-Arab patients on complementary medicine's role in cancer care E Ben-Arye, E Massalha, G Bar-Sela, M Silbermann, A Agbarya, B Saad, ... Annals of oncology 25 (2), 476-480, 2014 | 34 | 2014 |
| Anti-inflammation properties of fruiting bodies and submerged cultured mycelia of culinary-medicinal higher Basidiomycetes mushrooms RC Chien, LM Lin, YH Chang, YC Lin, PH Wu, MD Asatiani, SG Wasser, ... International Journal of Medicinal Mushrooms 18 (11), 2016 | 28 | 2016 |
| Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future CH Szeto, W Shalata, A Yakobson, A Agbarya Journal of Clinical Medicine 10 (23), 5614, 2021 | 27 | 2021 |
| Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trial E Ben‐Arye, D Hausner, N Samuels, D Gamus, O Lavie, T Tadmor, ... Cancer 128 (20), 3641-3652, 2022 | 24 | 2022 |
| Inhibitory Effect of Ethyl Acetate Extract of the Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (Higher Basidiomycetes) Fruit Bodies on Cell Growth of … A Rouhana-Toubi, SP Wasser, A Agbarya, F Fares International Journal of Medicinal Mushrooms 15 (5), 2013 | 21 | 2013 |
| 79MO PACIFIC-R: real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy F McDonald, F Mornex, MC Garassino, AR Filippi, D Christoph, ... Journal of Thoracic Oncology 16 (4), S738-S739, 2021 | 19 | 2021 |
| Compared perspectives of Arab patients in Palestine and Israel on the role of complementary medicine in cancer care E Ben-Arye, AMA Hamadeh, E Schiff, RM Jamous, J Dagash, RM Jamous, ... Journal of Pain and Symptom Management 49 (5), 878-884, 2015 | 18 | 2015 |
| Perceptions of complementary medicine integration in supportive cancer care of Arabs and Jews in Israel: a cross-cultural study E Ben-Arye, E Schiff, M Silbermann, A Agbarya, G Bar-Sela Journal of Pain and Symptom Management 49 (5), 871-877, 2015 | 18 | 2015 |
| Attitudes Among Nurses Toward the Integration of Complementary Medicine Into Supportive Cancer Care. E Ben-Arye, B Shulman, Y Eilon, R Woitiz, V Cherniak, IS Sharabi, O Sher, ... Oncology Nursing Forum 44 (4), 2017 | 15 | 2017 |
| Maintaining consistent bladder filling during external beam radiotherapy for prostate cancer NJ Nasser, E Fenig, J Klein, A Agbarya Technical innovations & patient support in radiation oncology 17, 1-4, 2021 | 14 | 2021 |
| Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC Registry G Mountzios, D Planchard, G Metro, D Tsiouda, A Prelaj, S Lampaki, ... JTO clinical and research reports 4 (1), 100433, 2023 | 13 | 2023 |
| Crizotinib in MET exon 14-mutated or MET-amplified in advanced disease non-small cell lung cancer: a retrospective, single institution experience W Shalata, A Yakobson, S Weissmann, E Oscar, M Iraqi, W Kian, N Peled, ... Oncology 100 (9), 467-474, 2022 | 12 | 2022 |
| Efficacy and safety of BRAF inhibitors with or without MEK inhibitors in BRAF-mutant advanced non–small-cell lung cancer: findings from a real-life cohort E Dudnik, J Bar, N Peled, E Bshara, T Kuznetsov, AY Cohen, T Shochat, ... Clinical Lung Cancer 20 (4), 278-286. e1, 2019 | 12 | 2019 |
